CLEC14A and neoplasm: This is the first study to propose use of an optimized antibody targeting CLEC14a‐CTLD, and the first study to demonstrate that CLEC14a‐CTLD is a novel anti‐angiogenic target for VEGF‐dependent angiogenesis and tumor angiogenesis.